Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Vaccines for melanoma.

Jean-Claude Bystryn¹

¹Ronald O. Perelman Department of Dermatology and Melanoma Program, Melanoma Immunotherapy Clinic, Kaplan Comprehensive Cancer Center, New York University School of Medicine, 35 East 35th Street, Suite 208, New York, NY 10016, USA. bystryn@nyu.edu

Dermatologic Clinics

|October 17, 2002

Summary

Melanoma vaccines are an accepted, experimental treatment for high-risk melanoma patients. Research is ongoing to enhance vaccine effectiveness by improving immune responses against melanoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.

Journal of the American Academy of Dermatology·2011

Same author

Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update.

Autoimmunity·2011

Same author

Serum levels of inhibitors of apoptotic proteins (IAPs) change with IVIg therapy in pemphigus.

The Journal of investigative dermatology·2011

Same author

Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies.

Journal of the American Academy of Dermatology·2010

Same author

Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid.

Medical hypotheses·2009

Same author

Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis.

Experimental dermatology·2009

Area of Science:

Oncology
Immunology
Vaccinology

Background:

Melanoma vaccines are an accepted, yet experimental, therapeutic option.
They are used in patients with surgically resected melanoma at high risk of recurrence.
Selected patients with advanced, limited melanoma also receive these vaccines.

Purpose of the Study:

To explore the correlation between immune response and clinical outcome in melanoma vaccine therapy.
To identify strategies for enhancing the efficacy of current-generation melanoma vaccines.
To establish the definitive effectiveness of vaccines in treating malignant melanoma.

Main Methods:

Investigating the relationship between vaccine-induced immune responses (cellular or antibody) and patient outcomes.
Developing and applying novel strategies to boost anti-melanoma immunity.
Conducting large-scale, prospective, randomized phase III clinical trials.

Main Results:

A general correlation exists between stimulated anti-melanoma immune responses and improved clinical outcomes.
Current research focuses on improving the immunogenicity of first-generation melanoma vaccines.
Several large phase III studies are underway to validate vaccine efficacy.

Conclusions:

Melanoma vaccines show promise, with effectiveness linked to immune stimulation.
Ongoing research aims to optimize vaccine strategies for better patient outcomes.
Definitive evidence of vaccine effectiveness in malignant melanoma treatment is being sought through rigorous clinical trials.

Related Experiment Videos